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Demonstration of the metaphylactic use of 
gamithromycin against bacterial pathogens 
associated with bovine respiratory disease in a 
multicentre farm trial
D. Baggott, A. Casartelli, F. Fraisse, C. Manavella, R. Marteau, S. Rehbein, 
M. Wiedemann, S. Yoon
On five commercial cattle rearing sites across Europe, a total of 802 young cattle at high risk 
of developing bovine respiratory disease (BRD) associated with the bacterial pathogens 
Mannheimia haemolytica or Pasteurella multocida and/or Mycoplasma bovis were 
enrolled into a multicentre, controlled field trial. Half were treated with a single dose of 
gamithromycin at 6 mg/kg bodyweight by subcutaneous injection and half received an 
injection of a saline placebo as the control. All animals were observed daily for 14 days 
for signs of BRD as defined by set criteria. The proportion of metaphylactic preventive 
treatment successes, defined as animals surviving to day 14 without signs of BRD, in the 
gamithromycin-treated group (86 per cent) was significantly (P=0.0012) higher than in the 
saline-treated controls (61 per cent). Morbidity among the treated animals was reduced by 
64 per cent compared with the controls.
THE conditions in which young, confined cattle are kept during the 
rearing process are conducive to the colonisation and proliferation of 
pathogens that cause bovine respiratory disease (BRD) (Bryson 2000, 
Macartney and others 2003, Radostits and others 2007). T ypical 
microorganisms associated with BRD include bacteria (Mannheimia 
haemolytica, Pasteurella multocida and Histophilus somni), Mycoplasma 
species and viruses (parainfluenza virus type 3, bovine respiratory 
syncytial virus, bovine viral diarrhoea virus and bovine herpesvirus 
type 1 [the cause of infectious bovine rhinotracheitis]) (Bryson 2000, 
Valarcher and Hagglund 2006).
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Although BRD is multifactorial in its pathogenesis, morbidity and 
mortality are usually the result of the pathophysiological responses to 
colonisation of the respiratory tract by pathogenic bacteria, such as 
M haemolytica, P multocida and H somni and Mycoplasma species (Mosier 
1997), hence the value of antibiotic therapy. The antibacterial agent 
gamithromycin was developed exclusively for veterinary use as a 
single dose, 150 mg/ml subcutaneous injectable solution (Zactran; 
Merial) for the therapeutic and preventive control of BRD associated 
with M haemolytica, P multocida and H somni. Gamithromycin is a novel 
semisynthetic macrolide of the azalide subclass. As for the macrolides 
in general, gamithromycin has a bacteriostatic action through inhibi-
tion of bacterial RNA-dependent protein synthesis, but based on in 
vitro studies it also can act in a bactericidal manner at concentrations 
that are reached in lung tissue (Retsema and others 1990, Jain and 
Danziger 2004). The macrolides generally, and the azalides even more 
so, achieve high concentrations for extended periods in the tissues, 
particularly lung tissue, compared with their concentrations in plasma 
(Bryskier and Bergogne-Berezin 1999). They also accumulate read-
ily in host defence cells, including polymorphonuclear leucocytes and 
macrophages, and readily distribute into extracellular fluid (Mattoes 
and Nightingale 2002). Gamithromycin shares the dose distribution 
and pharmacokinetic properties of the azalides (Huang and others 
2009). Coupled with its potent bactericidal activity, these properties 
make gamithromycin a strong candidate antibiotic for the treatment 
and control of BRD.
This paper describes a multicentre, randomised, controlled field 
trial designed to evaluate the efficacy of gamithromycin for the pre-
ventive treatment of BRD in Europe by comparing gamithromycin-
treated cattle with placebo-treated cattle.
Materials and methods
The trial was conducted in accordance with Good Clinical Practice 
guidelines (Anon 2000) for veterinary product development with the 
informed consent of the owners of the cattle involved. Five commer-
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in compliance with EU animal welfare regulations. After the trial, all 
gamithromycin-treated animals were held at the respective trial sites 
until they had fulfilled the locally approved investigational meat with-
drawal period for gamithromycin. Continuous exposure of enrolled 
animals to BRD pathogens was ensured throughout the trial by the 
presence of target pathogen carriers in the form of saline-treated con-
trol cattle and cattle that were not enrolled in the trial maintained in 
the same airspace as the gamithromycin-treated cattle.
Trial conduct
At each trial site, once BRD cases had been confirmed within the 
airspace occupied by the trial animals, cattle that were apparently 
healthy (those with depression and respiratory character scores of 0; 
Fig 1) were paired in order of presentation within groups of animals 
of similar bodyweight. Animals within each pair were randomly 
allocated to one of two treatment groups. All enrolled cattle were 
treated by subcutaneous injection on the same day (day 0) at each 
trial site: one group with 150 mg/ml gamithromycin solution at 6 
mg gamithromycin/kg bodyweight, and the other group with 0.9 
per cent sterile saline solution at 2 ml/kg bodyweight, as the control. 
Both treatment groups were commingled at all sites.
Animals were observed daily from the day of treatment for 
14 days for signs of BRD and general health. During these health 
observations, a clinical assessment of each animal was made to deter-
mine its BRD status, based on depression and respiratory character 
scores and the rectal temperature (Fig 1). Following treatment with 
gamithromycin or saline, enrolled cattle were removed from the study 
and treated as necessary with appropriate non-test drugs according 
to their therapeutic needs if they were diagnosed with BRD. Cattle 
were diagnosed with BRD if they fulfilled the clinical criteria of BRD 
(depression score >0, respiratory character score >0 and rectal tem-
perature ≥40.0°C) (Fig 1) for one day, or they showed clinical signs 
of BRD which, while not fulfilling all the clinical criteria of BRD, 
were considered severe enough by the attending veterinarian to jus-
tify removal on welfare grounds starting on day 1 (the day following 
treatment).
The trial monitoring period of 14 days was selected on the basis of 
an anticipated duration of antibacterial effect of gamithromycin of up 
to 15 days (depending on pathogen susceptibility) as estimated from 
pharmacokinetic, minimum inhibitory concentration (MIC) and total 
lung concentration data (Huang and others 2009).
Microbiology
At each trial site, before animals were enrolled, two nasopharyn-
geal samples were collected using sheathed, 20 to 27 cm long swabs 
(Medical Wire & Equipment) from each animal displaying clinical 
signs of BRD to confirm that the incidence of BRD at the site was 
5 per cent or more. The swabs were cultured to confirm the pres-
ence of the target BRD pathogens in the proposed study populations. 
The swabs were placed in appropriate transport media for the target 
pathogens, that is, one for culture of M bovis into mycoplasma trans-
port medium (Mycoplasma Experience) and the other for culture of 
M haemolytica, P multocida and H somni into Amies charcoal transport 
medium (Medical Wire & Equipment), and cultured and identified 
using standard procedures (Quinn and oth-
ers 2002). M bovis isolates were identified by 
culturing on a M bovis diagnostic agar medi-
um (Mycoplasma Experience) containing 
2,3,5-triphenyl tetrazolium chloride to pro-
duce red-centred colonies for M bovis only. 
Confirmed isolates of each pathogen were 
tested for in vitro susceptibility to gamithro-
mycin (except for M bovis, where only one 
isolate per trial site was tested) using broth 
dilution techniques, including quality con-
trol reference strains, to determine the MIC 
of gamithromycin (T able 2).
Data analysis
Data from each site separately and all sites 
combined were analysed to determine the 
cial cattle rearing units – one site in France and two sites in each of 
Germany and Italy – were included. A total of 802 male and female 
ruminating and younger, preruminating cattle were enrolled in the 
trial (T able 1). All had been recently assembled and/or commingled 
with other cattle into loose-housed pens. Routine disease control 
measures were similar for all animals at a trial site and were limited 
to administration of (but not necessarily any or all of) viral respiratory 
vaccines, endectocides and flukicides for the control of internal and 
external parasites, before or after arrival at the trial sites. None of the 
animals had received bacterial vaccines for BRD within the previous 
six months, or antimicrobials within 30 days before enrolment. T o 
minimise bias in the trial results, the investigators and all personnel 
performing post-treatment evaluations were masked to the treatment 
assignment of the animals.
At the time of enrolment in the trial, all animals included were con-
sidered healthy but with a high risk of BRD, on the basis that at least 10, 
equivalent to 5 per cent or more, of the cattle within the same airspace at 
each site had presented with clinical signs of BRD (depression score >0, 
abnormal respiration score >0 and rectal temperature 40.0°C or more 
[Fig 1]) over the previous 48 to 72 hours, and with M haemolytica, P multo-
cida and/or Mycoplasma bovis isolated on nasopharyngeal swabs (T able 2). 
Animals presenting with BRD before the start of the trial were treated 
according to their therapeutic needs with non-test drugs.
At each site, all animals were maintained within the same air-
space in naturally ventilated or controlled environment buildings and 
TABLE 1: Details of cattle at five sites used in a trial of the efficacy of gamithromycin in 
preventing clinical bovine respiratory disease
Number enrolled and 
treated
Number included in 
efficacy analysis
Trial site G* Control† Breeds Age (months) Weight (kg) G Control
France 43 44 CH, CC, L, BA, CB 7-23 152-582 42 43
Germany 1 60 60 FV <1-2 73-139 60 60
Germany 2 63 63 FV <1-3 54-88 61 63
Italy 1 121 121 CH, CC 7-18 198-390 121 121
Italy 2 113 114 S, A, L, CH, CC 4-18 200-430 113 114
Total 400 402 <1-23 54-582 397 401
* Treated with a single dose of 150 mg/ml gamithromycin injectable solution at 6 mg/kg (2 ml/50 kg) bodyweight 
† Treated with a single injection of sterile 0.9 per cent saline solution at 2 ml/50 kg bodyweight
A Aubrac, BA Blonde d’Aquitaine, CB Crossbred, CC Charolais cross, CH Charolais, FV Fleckvieh (German Simmental), 
L Limousin, S Saler
Depression score >0, and
Respiratory character score >0, and
Rectal temperature of ≥40.0°C
Cattle meeting the criteria for BRD were removed from the study and 
assessed by a veterinarian for treatment with non-test drugs according 
to therapeutic needs. Those with depression and/or respiratory 
character scores >2 were assessed for euthanasia on welfare grounds
Depression score
  0 Normal: nothing unusual in the animal’s attitude
   1   Mild depression: somewhat slow coming to the feed bunk, but did 
eat
   2   Moderate depression: slight drooping of the head/ears, reluctant to 
move about, reluctant to come to feed
   3   Severe depression: pronounced head/ear drooping; very reluctant 
to move
  4 Moribund (recumbent)
Respiratory character score
 0    Normal: no abnormal respiratory signs present. Respiratory rate 
and effort are appropriate for the environment
 1    Mild respiratory distress: serous and/or slight mucous nasal or 
ocular discharge and/or cough
 2    Moderate respiratory distress: mucopurulent or copious mucous 
nasal or ocular discharge and/or increase in respiratory rate or 
effort
 3    Severe respiratory distress: marked increase in respiratory rate 
or effort including one or more of the following: open-mouth 
breathing, abdominal breathing or head extended
FIG 1: Clinical criteria of bovine respiratory disease (BRD)
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efficacy of gamithromycin. It was considered appropriate to combine 
the data for ruminating and preruminating cattle from all sites because 
of similar gamithromycin pharmacokinetic profiles (Anon 2008) and 
BRD pathogenesis in both age groups.
On day 14, a treatment success was declared for cattle that were 
not diagnosed with BRD. Cattle that were removed from the trial 
for reasons other than BRD were not considered in the analysis of 
treatment success. The pivotal determinant of preventive efficacy was 
the proportion of BRD prevention treatment successes on day 14 in 
the gamithromycin-treated group compared with the saline-treated 
control group. For each individual site, the proportion of treatment 
  successes on day 14 was compared between the gamithromycin-
treated group and controls by Fisher’s exact test. The proportion of 
treatment successes on day 14 combined across all sites was analysed 
by a generalised linear model with a logit link function and a binomial 
distribution, where model factors included treatment as a fixed effect, 
and site and treatment by site interaction as random effects. A two-
sided significance level of 0.05 was used for all analyses, which were 
performed using the procedures of SAS Version 8.2 (SAS Institute).
Results
During the trial, no animals died as a result of BRD, and no adverse 
events considered to be related to the gamithromycin treatment 
occurred. T wo gamithromycin-treated animals and one saline-treat-
ed control animal were removed from the trial on welfare grounds 
for reasons not related to BRD (abdominal colic and non-specific 
enteritis), and thus were excluded from the analysis of preventive 
treatment success. One animal at the site in France was uninten-
tionally underdosed and was also excluded from the data analysis. 
Consequently, datasets from 397 animals treated with gamithromy-
cin and 401 treated with saline were available for the analysis of 
preventive treatment success.
The pre-enrolment isolations of intranasal BRD pathogens at the 
trial sites are shown in T able 2. The ranges of MICs of gamithromycin 
determined for the isolates of each BRD pathogen species are shown 
in T able 2.
The proportion of preventive treatment successes in the com-
bined gamithromycin-treated groups (86 per cent) was significantly 
(P<0.002) higher than in the combined sterile saline-treated controls 
(61 per cent) (T able 3). The higher success rate in gamithromycin-treat-
ed cattle was statistically significant (P<0.0001) at all individual trial 
sites except the site in France, where the total number of animals was 
relatively low compared with the other sites, thus reducing the sta-
tistical power for the data from this site. The overall BRD morbidity 
in the trial population (equivalent to the percentage of BRD-affected 
cattle among the controls) was 39 per cent, ranging from 72 and 63 
per cent, respectively, at the two sites in Germany to 26 to 28 per cent 
at the sites in Italy and France. Morbidity among the treated animals 
was lower overall by 64 per cent (32 to 82 per cent at individual sites) 
compared with the controls.
Discussion
Based on clinical assessment, this trial showed that gamithromy-
cin is effective in reducing the morbidity of bacterial BRD under 
field conditions in Europe when administered as a single subcutane-
ous preventive dose of 6 mg/kg bodyweight to cattle at high risk of 
developing BRD associated with M haemolytica, P multocida and/or 
M bovis.
Most isolates collected from cases of BRD at the trial sites before 
enrolment were considered susceptible to gamithromycin on the basis 
of the clinical outcomes, despite some M bovis isolate MICs being high 
(T able 2). It has been demonstrated that for macrolide antimicrobial 
compounds in particular, in vitro MIC sensitivity tests are greatly 
affected by methodological differences, such as the pH of the medium, 
variations in the medium and the inoculum size, with small increases 
in pH, for example, increasing the MIC by up to four times (Ben Ali 
and others 2002, Godinho and others 2005). Therefore, some mac-
rolide MICs may be poor indicators of clinical efficacy, as appears to 
be the case for some M bovis isolates from 
this trial.
The morbidities in the control cattle at 
the two sites in Germany were higher (63 to 
72 per cent) than at the other three sites (26 
to 28 per cent). Also at the German sites, 
morbidities in the treated animals (25 to 32 
per cent) were higher than at other sites (5 
to 19 per cent) even though the reduction 
in morbidity in treated animals compared 
with controls was high at approximately 60 
per cent. At these sites, the animals studied 
were young calves less than three months 
old and had a more diverse bacterial flora 
than older cattle at other sites (T able 2). The 
bacterial pathogens isolated from the sites 
in Germany were shown to be susceptible 
to gamithromycin by in vitro MIC testing 
(MIC 0.125 to 2.0 μg/ml) (T able 2), so it is 
assumed that the relatively high morbidity 
among the test animals in Germany reflect-
TABLE 2: Pre-enrolment incidence (%) of bovine respiratory disease (BRD) and isolations of causative bacterial and mycoplasmal pathogens 
at the five trial sites, and in vitro minimum inhibitory concentration (MIC) of gamithromycin of the isolates
Number of animals
Number of animals Number (%) Sampled Positive for BRD Number of samples positive for pathogens (MIC gamithromycin range [μg/ml])
Trial site  in airspace  with BRD  (nasal swabs) pathogens Pm Mh Hs Mb
France 97 10  (10.3) 8 2  0  2  (1.0) 0  1
Germany 1 93* 18 (19.4) 18 12   5 (0.125-2.0    8 (0.5-1.0) 0   4
Germany 2 279 34 (12.2) 34 15   9 (0.25-2.0)    2 (0.5-2.0) 0   7
Italy 1 281 34 (12.1) 34 22   0   2 (1.0) 0 22
Italy 2 249 22 (9.0) 22 12   0 12 (not tested) 0   0
Total 116 63 14 (0.125-2.0) 26 (0.5-2.0) 0 34 (>16)†
* Additional study animals were added to the airspace after nasal swabs were collected
† MIC range based on one randomly selected isolate per trial site
Hs Histophilus somni, Mb Mycoplasma bovis, Mh Mannheimia haemolytica, Pm Pasteurella multocida
TABLE 3: Efficacy of a single dose of gamithromycin in preventing bovine respiratory disease 
(BRD), shown as the number and proportion of treatment successes and the percentage 
morbidity, assessed 14 days after treatment
Gamithromycin* Control†
Trial site
Number (%) of 
treatment successes Morbidity‡ (%)
Number (%) of 
treatment successes Morbidity (%)
Morbidity 
reduction (%) P
France 34/42 (81) 19 31/43 (72) 28 32 0.4444§
Germany 1 41/60 (68) 32 17/60 (28) 72 56 <0.0001§
Germany 2 46/61 (75) 25 23/63 (37) 63 60 <0.0001§
Italy 1 113/121 (93) 7 90/121 (74) 26 73 <0.0001§
Italy 2 107/113 (95) 5 82/114 (72) 28 82 <0.0001§
Total 341/397 (86) 14 243/401 (61) 39 64 0.0012∞
* Gamithromycin 150 mg/ml injectable solution at 6 mg/kg (2 ml/50 kg) bodyweight
† Sterile 0.9 per cent saline solution at 2 ml/50 kg bodyweight
‡ Morbidity is the percentage of BRD cases in the control or gamithromycin-treated groups. Morbidity reduction is the ratio 
of morbidity in gamithromycin-treated cattle to controls
§ Probability from Fisher’s exact test for the proportion of treatment success in the individual trial site in gamithromycin-
treated versus saline-treated control groups
∞ Probability from generalised linear model analysis for the proportion of treatment success in the combined 
gamithromycin-treated versus saline-treated control groups
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ed the greater susceptibility of younger animals to BRD and possibly 
the presence of non-susceptible respiratory pathogens, such as viruses, 
that were not identified.
The sites of bacterial multiplication and initial pathology for BRD 
pathogens are thought to be on the surface of bronchiolar and alveo-
lar lining cells and in the adjacent pulmonary epithelial lining fluid 
(PELF) (Nightingale and Mattoes 2002). Although gamithromycin 
concentration measurements in whole lung homogenate, as reported 
by Huang and others (2009), do not provide a quantitative measure of 
the drug concentration in PELF, a further study (Giguère and others 
2011) has reported rapid penetration of all lung tissues within 30 min-
utes of administration, with mean gamithromycin concentrations in 
calf PELF and associated cells peaking at 24 hours (4.6 and 17.8 μg/ml, 
respectively) and remaining above 0.5 μg/ml for at least seven days 
after treatment. It is probable, therefore, that the concentration of 
gamithromycin in PELF stays above the in vitro gamithromycin MIC 
90 per cent (MIC90) for the principal target BRD pathogens (0.5 to 1.0 
μg/ml) (Huang and others 2009) beyond seven days after treatment. 
The efficacy due to the extended duration of high levels of gamithro-
mycin in PELF is further enhanced by the long postantibiotic effect 
(the duration of antibacterial effects in vitro after removal of the anti-
biotic) of up to eight hours, which is typical of modern macrolides 
(Diarra and others 1999).
In most regions of the world, there are strong initiatives in place to 
encourage the responsible use of antimicrobials in veterinary practice 
(European Platform for the Responsible Use of Medicines in Animals 
2008, British Veterinary Association 2009). The use of antibiotics in 
the control of BRD can be broadly classified as either therapeutic, in 
which animals with clinical disease are treated, or preventive, when 
groups of animals are treated before the onset of disease in order to 
limit the potential impact of BRD. Preventive approaches can be fur-
ther subdivided into prophylactic, when antibiotics are administered 
before the appearance of clinical disease to groups of cattle judged to be 
at high risk of developing BRD, and metaphylactic, in which antibiot-
ics are administered to cohorts of apparently healthy animals that are 
in contact with clinical cases (Brumbaugh 2009). Using these defini-
tions, the present study involved a metaphylactic approach. While 
the decision by veterinarians to adopt any of these approaches rests 
on numerous considerations, one of the most important is the welfare 
of the animals under their care. A therapeutic approach will gener-
ally result in the lowest level of antibiotic usage, but this requires a 
high level of stockmanship in order to detect BRD in its early stages, 
and adequate labour and facilities with which to handle, examine 
and treat the affected animals promptly, if their welfare is not to be 
compromised. When determining what approach should be used, the 
relative risk of infection and its consequences must be sufficient to 
outweigh the risks associated with using an antimicrobial drug. Risk 
of infection is related to the virulence of the organism(s), the amount 
of exposure of the animal to the organism(s) and the animal’s immune 
defence status (Brumbaugh 2009). The virulence of the organisms 
and the amount of exposure can be predicted on the basis of previ-
ous experience of the disease at the farm/facility, including specific 
diagnosis and isolation of pathogens, and estimates of morbidity and 
mortality when possible. The animals’ defence status can be predicted 
by knowledge of the physiological and immunological characteristics 
of the animals at risk; thus, their age, the stressors to which they are 
exposed, their previous exposure to disease and their vaccination sta-
tus should all be considered. In the trial described in this paper, which 
employed a metaphylactic approach, the risk of BRD was based on 
5 per cent or more of the cattle within the airspace having presented 
with clinical signs of BRD after assembly and/or commingling at 
the trial site. This resulted in actual morbidities of 28 to 72 per cent 
among the control animals. The treatment with gamithromycin sig-
nificantly reduced morbidity by 64 per cent overall (32 to 82 per cent 
at individual sites), confirming that the predicted consequences of not 
treating in terms of morbidity in untreated animals justified the use of 
the product by improving the welfare of the animals.
Part of the rationale for responsible use of antimicrobials is to limit 
the exposure of bacteria to sublethal levels of antibiotics in order to 
reduce the selection for antibiotic resistance. The pharmacokinetic/
pharmacodynamic profile of 15-membered ring azalides such as 
gamithromycin is almost unique among antimicrobial agents: high 
tissue concentrations, rapid accumulation in tissues, retention by mac-
rophages and circulating phagocytes, long elimination half-life and 
prolonged postantibiotic effect. These properties of azalides, which 
include gamithromycin, coupled with appropriate use, reduce the 
potential for development of resistance against this subclass more 
than for many other antibiotic classes used in veterinary medicine 
(Retsema 1999).
In conclusion, this European multicentre field trial has shown that 
gamithromycin, administered as a single treatment using a metaphy-
lactic approach to at-risk cattle kept under a wide range of commercial 
conditions, significantly reduced the clinical incidence of BRD associ-
ated with M haemolytica, P multocida and/or M bovis over the 14-day trial 
observation period.
Acknowledgements
The authors thank the owners of the animals involved, Fabrizio Solari 
Basano and all personnel at Arcoblu, Milan, Italy, for coordinating 
the Italian studies, Mycoplasma Experience Limited for the isolation 
of Mycoplasma bovis from nasal swabs, and many other colleagues for 
their assistance with the conduct of the trial and the preparation of 
the manuscript, in particular A. B. Forbes, B. Somerville and R. K. 
T essman. This study was funded by Merial Limited, Duluth, GA 
30096, USA.
References
ANON (2000) International Cooperation on Harmonisation of T echnical Requirements 
for Registration of Veterinary Medicinal Products (VICH). Guideline (GL9) Good 
Clinical Practice. European Medicines Agency. www.ema.europa.eu/docs/en_GB
/document_library/Scientific_guideline/2009/10/WC500004343.pdf. Accessed 
February 23, 2010
ANON (2008) Zactran Summary of Product Characteristics. Committee for Medicinal 
Products for Veterinary Use, European Medicines Agency
BEN ALI, A., GOLDSTEIN, F. W. & ACAR, J. F. (2002) In vitro activity of macrolides 
against traditional susceptible bacteria. In Macrolide Antibiotics. Eds W. Schönfeld, 
H. A. Kirst. Birkhäuser Verlag. pp 185-200
BRITISH VETERINARY ASSOCIATION (2009) Responsible Use of Antimicrobials in 
Veterinary Practice. http://www.bva.co.uk/public/documents/BVA_Antimicrobials_
Poster.PDF. Accessed February 23, 2010
BRUMBAUGH, G. W. (2009) Principles of antimicrobial therapy: prophylactic or met-
aphylactic use of antimicrobial drugs. In Large Animal Internal Medicine. 4th edn. 
Ed B. P. Smith. Mosby Elsevier. pp 1517-1519
BRYSKIER, A. & BERGOGNE-BEREZIN, E. (1999) Macrolides. In Antimicrobial 
Agents. Ed A. Bryskier. ASM Press. pp 475-526
BRYSON, D. G. (2000) The calf pneumonia complex – current thoughts on aetiology. 
Cattle Practice 8, 103-107
DIARRA, M. S., MALOUIN, F. & JACQUES, M. (1999) Postantibiotic and physiologi-
cal effects of tilmicosin, tylosin, and apramycin at subminimal and suprainhibitory con-
centrations on some swine and bovine respiratory tract pathogens. International Journal 
of Antimicrobial Agents 12, 229-237
EUROPEAN PLATFORM FOR THE RESPONSIBLE USE OF MEDICINES IN 
ANIMALS (2008) Best-Practice Framework for the Use of Antimicrobials in Food-
producing Animals in the EU. www.epruma.eu/topics/antimicrobials-in-food-
producing-animals.html. Accessed February 23, 2010
GIGUÈRE, S., HUANG, R., MALINSKI, T., DORR, P., TESSMAN, R. K. & 
SOMERVILLE, B. (2011) Disposition of gamithromycin in plasma, pulmonary epi-
thelial lining fluid, bronchoalveolar cells, and lung tissue in cattle. American Journal of 
Veterinary Research (In press) 
GODINHO, K. S., RAE, A., WINDSOR, G. D., TILT, N., ROWAN, T. G. & 
SUNDERLAND, S. J. (2005) Efficacy of tulathromycin in the treatment of bovine 
respiratory disease associated with induced Mycoplasma bovis infections in young dairy 
calves. Veterinary Therapeutics 6, 96-112
HUANG, R. A., LETENDRE, L. T., BANAV, N., FISCHER, J. & SOMERVILLE, B. 
(2009) Pharmacokinetics of gamithromycin in cattle with comparison of plasma 
and lung tissue concentrations and plasma antibacterial activity. Journal of Veterinary 
Pharmacology and Therapeutics 33, 227-237
JAIN, R. & DANZIGER, L. H. (2004) The macrolide antibiotics: a pharmacokinetic and 
pharmacodynamic overview. Current Pharmaceutical Design 10, 3045-3053
MACARTNEY, J. E., BATEMAN, K. G. & RIBBLE, C. S. (2003) Health performance of 
feeder calves sold at conventional auctions versus special auctions of vaccinated or condi-
tioned calves in Ontario. Journal of the American Veterinary Medical Association 223, 677-683
MATTOES, H. M. & NIGHTINGALE, C. H. (2002) Pharmacokinetics/pharmaco-
dynamics of macrolides. In Macrolide Antibiotics. Eds W. Schonfeld, H. A. Kirst. 
Birkhauser Verlag. pp 25-36
MOSIER, D. A. (1997) Bacterial pneumonia. Veterinary Clinics of North America: Food Animal 
Practice 13, 483-493
NIGHTINGALE, C. H. & MATTOES, H. M. (2002) Macrolide, azalide and ketolide phar-
macodynamics. In Antimicrobial Pharmacodynamics in Theory and Clinical Practice. 
Eds C. H. Nightingale, T. Murakawa, P. G. Ambrose. Marcel Dekker. pp 205-220
QUINN, P. J., MARKEY, B. K., DONNELLY, W. J. & LEONARD, F. C. (2002) Pathogenic 
bacteria: Pasteurella species and Mannheimia haemolytica, and Haemophilus species. In 
Veterinary Microbiology and Microbial Disease. Blackwell Science. pp 137-151
P035550.indd   Sec1:4 P035550.indd   Sec1:4 3/3/2011   6:09:03 PM 3/3/2011   6:09:03 PMMarch 5, 2011 | Veterinary Record
Papers
RADOSTITS, O. M., GAY, C. C., HINCHCLIFF, K. W. & CONSTABLE, P. D. (2007) 
Bovine respiratory disease. In Veterinary Medicine: A T extbook of the Diseases of 
Cattle, Sheep, Pigs, Goats and Horses. 10th edn. Saunders Elsevier. pp 923-946
RETSEMA, J. A. (1999) Susceptibility and resistance emergence studies with macrolides. 
International Journal of Antimicrobial Agents 11 (Suppl 1), S15-21
RETSEMA, J. A., GIRARD, A. E., GIRARD, D. & MILISEN, W. B. (1990) Relationship 
of high tissue concentrations of azithromycin to bactericidal activity and efficacy in 
vivo. Journal of Antimicrobial Chemotherapy 25 (Suppl A), 83-89
VALARCHER, J. F. & HAGGLUND, S. (2006) Viral respiratory infections in cattle. 
Proceedings of the World Buiatrics Congress. Nice, October 15 to 19, 2006. pp 384-397
P035550.indd   Sec1:5 P035550.indd   Sec1:5 3/3/2011   6:09:03 PM 3/3/2011   6:09:03 PM